Synaffix, a Dutch entity providing clinical-stage platform technology for the development of ADCs, reports the expansion of its license agreement with MacroGenics Inc.
The extension comes just a year after their original February 2022 deal.
A biopharma company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, MacroGenics has the option to pursue up to seven ADC programs under the expanded deal, which includes three programs from the original tie-up.
Under the original licensing deal, MacroGenics gained access to Synaffix’s clinical stage GlycoConnect antibody conjugation and HydraSpace polar spacer technologies, as well as select toxSYN linker-payloads. They are combined with MacroGenics’ antibody and bispecific DART platform technologies to generate next-generation ADCs.
Out-licensing business model
The Synaffix business model is based on target-specific technology out-licensing. The firm claims the combination of its three technologies provides companies with a ‘one stop’ and easy-to-use ADC technology platform, allowing any antibody developer to develop its own proprietary ADC and increase its competitive position.
“The expansion of our agreement with MacroGenics is a significant milestone for Synaffix that further underscores the growing momentum behind our proprietary ADC technology.
“There are now 13 companies that have publicly disclosed the development of more than 20 ADCs built using our technology, with five programs that have commenced clinical development to date,” commented Anthony DeBoer, VP of business development at Synaffix.
The Netherlands-based player signed off on two key deals in January this year, one with Amgen and the other with Hummingbird Biosience.
